This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Simdax
  • /
  • Repetitive Levosimendan Infusion for Patients With...
Clinical trial

Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure (LeoDOR)

Read time: 3 mins
Last updated:8th Mar 2018
Identifier: NCT03437226

Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design.

Mortality and rehospitalisation rates are high in the vulnerable phase following heart failure hospitalisation. Previous studies suggest that these events can be reduced by repeat infusions of levosimendan in patients with advanced heart failure.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 264 participants
Allocation : Randomized
Intervention Model : Parallel Assignment
Masking : Triple (Participant, Care Provider, Investigator)
Primary Purpose : Treatment
Official Title : Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
Actual Study Start Date : March 8, 2018
Estimated Primary Completion Date : April 1, 2019
Estimated Study Completion Date : December 31, 2019

Arm:
- Experimental :
Levosimendan Arm
- Placebo Comparator : Placebo Arm

Related journal :
- Repetitive levosimendan treatment in the management of advanced heart failure.

Category Value
Date last updated at source 2018-08-22
Study type(s) Interventional
Expected enrolment 264
Study start date 2018-03-08
Estimated primary completion date 2019-04-01

View full details